Article

Challenges, Risks And Strategies For Biologic Substance Manufacturing

Source: Thermo Fisher Scientific
Challenges, Risks And Strategies For Biologic Substance Manufacturing

ORC International’s study highlights issues inherent in forecasting biologic drug substances. From discussions with pharmaceutical and biotechnology industry leaders, it is clear that demand forecasting is a significant challenge when planning biologic drug substance production. The biologics development and approval process is typically long and complicated, increasing the risk of inaccurately forecasting demand. Overestimating demand can lead to higher per unit cost and disposal expenses, and underesti­mating it can result in missed market opportunities and negative reputational consequences for the company.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene